CURE is pleased to announce that Dr. Chris Senanayake has joined CURE’s Board of Directors.

Chris is currently Vice President, Chemical Development, at Boehringer Ingelheim Pharmaceuticals. His research interests focus on the development of new asymmetric methods for the synthesis of bioactive molecules and heterocycles and on catalytic, enzymatic, and mechanistic studies.

 

In 2010, he received the prestigious Siegfried gold medal award for development of practical processes for APIs and Process Chemistry.